Mineralys Therapeutics Stock Earnings Reports

Mineralys reported Q1 2026 results and provided a corporate update centered on lorundrostat. The FDA accepted the NDA for lorundrostat for use in adults with hypertension (in combination with other antihypertensives) and set a PDUFA date of December 22, 2026. The NDA is supported by five clinical trials (Launch-HTN, Advance-HTN, Transform-HTN OLE, Target-HTN, Explore-CKD) showing clinically meaningful, durable blood pressure reductions with a favorable tolerability profile. The company plans an initial commercial focus on the high-need fourth-line (resistant) hypertension population, is engaging payers and physicians, building commercial and medical affairs capabilities, and continuing to explore partnering opportunities. Financially, Mineralys ended Q1 with $646.1M in cash, cash equivalents and investments and believes this runway supports operations into 2028. R&D spend declined year-over-year following pivotal program completion; G&A rose with prelaunch build-out. Q1 net loss was $39.3M. Management views AstraZeneca’s expected earlier ASI launch as a net positive for market awareness and emphasizes differentiation through Mineralys’ distinct datasets (notably Advance-HTN and Explore-CKD) and diverse trial populations. Ongoing priorities include prelaunch market access, payer discussions, guideline engagement, publication of long-term safety/efficacy data, and continued evaluation of partnership options.